In the Original Investigation titled “Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial,”¹ published in December 2019, there were errors in Table 2 and Figure 2. In Table 2, the table header “30 mg (n = 45)” in the fourth column should have cited table note “b,” not “a.” In Figure 2, panels B and C should have been labeled “Percentage change in EASI” and “Patients with ≥4-point improvement in pruritis NRS score,” respectively. This article was corrected online.

中文翻译：

---

表2和图2中的错误。

在原反倾销调查名为“疗效和口服Janus激酶抑制剂1的Abrocitinib安全性异位性皮炎患者：第2阶段随机临床试验，” ¹发表在2019年十二月，共有在表2和图2。在表2中的错误，第四栏中的表格标题“ 30 mg（n = 45）”应引用表格注释“ b”，而不是“ a”。在图2中，面板B和C分别应标记为“ EASI的百分比变化”和“瘙痒性NRS得分提高4分以上的患者”。本文已在线更正。